Friendly skin bacteria could hold the key to stopping eczema in its tracks, according to a breakthrough by a team of UK and Japanese scientists. Their study, published in Nature Communications, shows harmless microbes living on our skin can release powerful molecules that counteract Staphylococcus aureus, a bug long known for causing havoc in eczema patients.
The research team, based at the University of Manchester and Tokyo University of Agriculture and Technology, discovered that when nutrients are scarce, many friendly staphylococcal species produce tiny lipopeptides as they age. These lipopeptides have been found to inhibit keratinocytes—the skin's frontline cells—from pumping out Interleukin-33 (IL-33), a major driver of allergic inflammation.
The findings suggest that good bacteria might naturally counteract the inflammatory response triggered by Staphylococcus aureus, potentially leading to new treatments for eczema. When applied to mice with skin lesions, lipopeptides prevented IL-33 release and halted the development of eczema symptoms.
Dr. Peter Arkwright from The University of Manchester these lipopeptides are small, stable, non-infectious chemical structures that could be used as topical treatments for eczema. "We think this is a very exciting result," he said. "Lipopeptides might also have potential in treating other allergic diseases such as hay fever."
The study builds on previous research by the same team, which showed that blocking IL-33 with biologic drugs can prevent eczema flare-ups. Now, they've found that bacteria themselves can produce these lipopeptides to suppress IL-33 release.
Dr. Joanne Pennock from The University of Manchester noted, "For years we've known that children raised around farm animals or exposed to diverse microbes early in life are less likely to develop allergies, but we haven't understood the precise mechanisms behind this protection."
Professor Akane Tanaka from Tokyo University of Agriculture and Technology added, "We have previously shown that blocking IL-33 with a biologic drug stops eczema. Now we've shown bacteria can do it themselves—an exciting and potentially game-changing discovery."
The next step is to test these lipopeptides in human clinical trials for eczema treatment. Professor Hiroshi Matsuda from Tokyo University of Agriculture and Technology emphasized, "Our findings overturn long-held assumptions about how bacterial molecules behave. Instead of triggering immune alarms through TLR pathways, these lipopeptides bypass them entirely."
The discovery opens up new avenues for treating not only eczema but also other allergic diseases like hay fever. As Dr. Arkwright noted, "Lipopeptides might be used in the future to treat other allergic conditions as well."
